Press Release 26 November 2026 13:47:00 CET

Faron Pharmaceuticals: First patient dosed in phase IIb BEXERA trial

Redeye's analyst just published a Research Note on Faron Pharmaceuticals.
Click here to read the article
Make sure to add Faron Pharmaceuticals to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies

About Redeye Nordic Growth AB

This is a press release from Redeye Nordic Growth AB, a equity research firm specializing in Nordic growth companies within Tech and Life Science. Redeye Nordic Growth is a part of the Redeye group, which also offers services within corporate finance advisory and fund management. https://services.redeye.se/

Attachments

Faron Pharmaceuticals: First patient dosed in phase IIb BEXERA trial